Abstract
Central obesity is a leading health concern with a great burden carried by ethnic minority populations, and especially Hispanics/Latinos. Genetic factors contribute to the obesity burden overall and to inter-population differences. We aim to: 1) identify novel loci associated with central adiposity measured as waist-to-hip ratio (WHR), waist circumference (WC), and hip circumference (HIP), all adjusted for body mass index (adjBMI), using the Hispanic Community Health Study/Study of Latinos (HCHS/SOL); 2) determine if differences in genetic associations differ by background group within HCHS/SOL; 3) determine whether previously reported association regions generalize to HCHS/SOL. Our analyses included 7,472 women and 5,200 men of mainland (Mexican, Central and South American) and Caribbean (Puerto Rican, Cuban, and Dominican) background residing in the US, with genome-wide array data imputed to the 1000 genomes Phase I multiethnic reference panel. We analyzed associations stratified by sex in addition to sexes combined using linear mixed-model regression. We identified 16 variants for WHRadjBMI, 22 for WCadjBMI, and 28 for HIPadjBMI that reached suggestive significance (P<1×10−6). Many of the loci exhibited differences in strength of associations by ethnic background and sex. We brought a total of 66 variants forward for validation in nine cohort studies (N=34,161) with participants of Hispanic/Latino, African and European descent. We confirmed four novel loci (ancestry-specific P<0.05 in replication, consistent direction of effect with HCHS/SOL, and P<5×10−8 after meta-analysis with HCHS/SOL), including rs13301996 in the sexes-combined analysis, and rs79478137 for women-only for WHRadjBMI; rs28692724 in women-only for HIPadjBMI; and rs3168072 in the sexes combined analysis for WCadjBMI. Also, a total of eight previously reported WHRadjBMI association regions, 12 for HIPadjBMI, and 10 for WCadjBMI generalized to HCHS/SOL. Our study findings highlight the importance of large-scale genomic studies in ancestrally diverse Hispanic/Latino populations for identifying and characterizing central obesity-susceptibility that may be ancestry-specific.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AEJ was supported in part by National Institute of Health (NIH), National Heart, Lung, and Blood Institutes (NHLBI) grant K99/R00 HL 130580 and American Heart Association (AHA) grant 13POST16500011. YCK is supported by the National Heart, Lung, and Blood Institutes (R01-HL136528). HMH was supported in part by NIH NHLBI grant T32 HL007055.
HCHS/SOL: The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), Universit y o f Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago - HHSN268201300003I / N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at the University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and MOD03).
ARIC: The Atherosclerosis Risk in Communities Study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.
GUARDIAN, MACAD, HTN-IR, GOLDR: This research was supported by the GUARDIAN (Genetics Underlying Diabetes in Hispanics) Study, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) contract DK085175; (Mexican-American Coronary Artery Disease (MACAD) National Heart, Lung, and Blood Institute, contracts R01-HL088457, R01-HL-60030; National Heart, Lung, and Blood Institute, Hypertension and Insulin Resistance (HTN-IR) contracts R01-HL067974, R01-HL-55005, R01-HL 067974; National Institutes of Health, Genetics of Latino Diabetic Retinopathy (GOLDR) contract EY014684.
MESA: MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420. Also supported by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
The Mexico City 1 and Mexico City 2 studies were supported in Mexico by the Fondo Sectorial de Investigacion en Salud y Seguridad Social (SSA/IMSS/ISSSTECONACYT, project 150352), Temas Prioritarios de Salud Instituto Mexicano del Seguro Social (2014-FIS/IMSS/PROT/PRIO/14/34), and the Fundacion IMSS. In Canada, this research was enabled in part by two CIHR Operating grants to EJP, a CIHR New Investigator Award to EJP and by support provided by Compute Ontario (www.computeontario.ca), and Compute Canada (www.compute.canada.ca).
WHI: Funding support for the Epidemiology of putative genetic variants: The Womens Health Initiative study is provided through the NHGRI grants HG006292 and HL129132. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSC271201100004C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies have received ethical and study protocol approval from their respective institutional review boards (IRBs) in accordance with the principles outlined in the Declaration of Helsinki. HCHS/SOL Study: Original data collection for HCHS/SOL was approved by each field center’s IRB where all subjects gave written informed consent, including University of Illinois at Chicago, University of Miami, San Diego State University, Albert Einstein College of Medicine, and the coordinating center at University of North Carolina at Chapel Hill. For data analysis specific to this project, this study was reviewed by the University of North Carolina at Chapel Hill’s Institutional Review Board. As this analysis including de-identified and previously collected data it was determined exempt (non-human subjects research). ARIC: Original data collection for HCHS/SOL was approved by each field center’s IRB where all subjects gave written informed consent, including John Hopkins Bloomberg School of Public Health, University of Mississippi Medical Center, University of Minnesota, and the University of North Carolina at Chapel Hill IRB. For data analysis specific to this project, this study was reviewed by the University of North Carolina at Chapel Hill’s Institutional Review Board. As this analysis including de-identified and previously collected data it was determined exempt (non-human subjects research). GUARDIAN Consortium: All participants gave written, informed consent for participation in the study, which was approved by the Institutional Review Board of each study site and coordinating center, including LAC+USC Medical Center, The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center. MESA: All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. Mexico City: This study was approved by the ethical research board (Comite Local de Investigacion) of the Medical Center Siglo XXI. WHI: All WHI participants provided informed consent. This study was approved by the IRB at University of North Carolina at Chapel Hill. PELOTAS: This study is approved by the Federal University of Pelotas Ethical Committee. STARR County: This study was approved by the IRB at the Uiversity of Texas Health Sciences Center at Houston. Additional details on recruitment, including form of informed consent, for each study can be found in study design publications referenced in Supplementary Table 1.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¶ The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
Data Availability
Raw genetic data used in the discovery analysis for this project is available through request on dbGAP (dbGaP Study Accession: phs000810.v1.p1). Additionally, the full GWAS summary results for common variants with a MAF<1% will be made available upon request to the author and on the NHGRI-GWAS Catalog (upon publication).
